ReviewCPT: pharmacometrics & systems pharmacology2024
Covariate modeling in pharmacometrics: General points for consideration.
Review in CPT: pharmacometrics & systems pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Covariate Model Selection Approaches for Population Pharmacokinetics: A Systematic Review of Existing Methods, From SCM to AI.CPT: pharmacometrics & systems pharmacology · 2025Pooled it
- Population pharmacokinetics of imipenem in different populations for individualized dosing: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Pooled it
- Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment.Journal of clinical pharmacology · 2026Trial
- Identification of Microbiome Associations with Tacrolimus Pharmacokinetics in Adult Hematopoietic Cell Transplantation Using Population Pharmacokinetic and Machine Learning.Pharmaceutical research · 2026Observational
- PMX-CovEval: A Framework Including a Simulated Pharmacokinetic Database for Covariate Model Building Methods Benchmarking.CPT: pharmacometrics & systems pharmacology · 2026Article
- PKGPT: Expert-Orchestrated Recursive LLM Agent for Automated NONMEM PopPK Modeling with Human Benchmarking.Pharmaceutics · 2026Article
- Assessing Covariate Clinical Relevance in High-Dimensional PK Analysis: A Comparison of SCM+, FFEM, and FREM Approaches.CPT: pharmacometrics & systems pharmacology · 2026Article
- SCOUT: An Exploratory Approach to Scouting Dose-Relevant Covariates.CPT: pharmacometrics & systems pharmacology · 2026Article
- When Survival Improves But Quality of Life Does Not: A Model-Based Meta-Analysis of Immune Checkpoint Inhibitors.medRxiv : the preprint server for health sciences · 2026Article
- Learning Covariate Relations in Disease Progression Models Using Symbolic Neural Networks.CPT: pharmacometrics & systems pharmacology · 2026Article
- Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses.CPT: pharmacometrics & systems pharmacology · 2026Article
- The Regularized Horseshoe for Covariate Selection Improves Convenience and Predictive Performance in Population PK/PD Models.CPT: pharmacometrics & systems pharmacology · 2026Article
- Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting.CPT: pharmacometrics & systems pharmacology · 2026Article
- Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling.CPT: pharmacometrics & systems pharmacology · 2026Article
- Artificial Intelligence and Predictive Modelling for Precision Dosing of Immunosuppressants in Kidney Transplantation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A short review of dose-finding adaptive trial designs for clinical pharmacologists and non-statisticians in oncology.European journal of clinical pharmacology · 2026Review
- Training the next-generation of biomedical scientists through artificial intelligence-driven education and research in pharmacology and pharmaceutical sciences.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- The Rational Basis for Personalized Treatment Using Concentration-Guided Dosing.Therapeutic drug monitoring · 2025Review
- Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.Clinical pharmacokinetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modeling the relationships between covariates and pharmacometric model parameters is a central feature of pharmacometric analyses. The information obtained from covariate modeling may be used for dose selection, dose individualization, or the planning of clinical studies in different population subgroups. The pharmacometric literature has amassed a diverse, complex, and evolving collection of methodologies and interpretive guidance related to covariate modeling. With the number and complexity of technologies increasing, a need for an overview of the state of the art has emerged. In this article the International Society of Pharmacometrics (ISoP) Standards and Best Practices Committee presents perspectives on best practices for planning, executing, reporting, and interpreting covariate analyses to guide pharmacometrics decision making in academic, industry, and regulatory settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.